ArticleGastroenterology research and practice2016
Expressions of Matrix Metalloproteinases (MMP-2, MMP-7, and MMP-9) and Their Inhibitors (TIMP-1, TIMP-2) in Inflammatory Bowel Diseases.
Article in Gastroenterology research and practice, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 74 citations in OpenAlex.
- Expression of inflammatory mediators in biofilm samples and clinical association in inflammatory bowel disease patients-a preliminary study.Clinical oral investigations · 2022Trial
- A review on MMP-2 modulating agents from natural and synthetic sources and their role in inflammatory bowel disease.Inflammopharmacology · 2026Review
- Article
- REG4 induces angiogenesis in ulcerative colitis by upregulating MMP-7 expression and downregulating sVEGFR1 level.European journal of medical research · 2025Article
- Angiogenic Factors and Inflammatory Bowel Diseases.Biomedicines · 2025Review
- Relationships between MMP-2, MMP-9, and ADAMDEC1 serum and tissue levels in patients with colorectal cancer.Annals of coloproctology · 2025Article
- The Construction Strategy of Curcumin Nanomedicine Delivery System and Its Application in the Treatment of Ulcerative Colitis.International journal of nanomedicine · 2025Review
- The Improvement of Intestinal Mucosal Epithelial Barrier Integrity by 1,3,4-Oxadiazole Derivatives of Pyrrolo[3,4-Journal of inflammation research · 2025Article
- Gut-liver translocation of pathogen Klebsiella pneumoniae promotes hepatocellular carcinoma in mice.Nature microbiology · 2025Article
- Article
- Transcriptional profiling identification of inflammatory signaling pathways in ulcerative colitis.PloS one · 2025Article
- Bioresponsive and transformable coacervate actuated by intestinal peristalsis for targeted treatment of intestinal bleeding and inflammation.Bioactive materials · 2024Article
- Biochemical Modulators of Tight Junctions (TJs): Occludin, Claudin-2 and Zonulin as Biomarkers of Intestinal Barrier Leakage in the Diagnosis and Assessment of Inflammatory Bowel Disease Progression.Molecules (Basel, Switzerland) · 2024Article
- Identification of hub programmed cell death-related genes and immune infiltration in Crohn's disease using bioinformatics.Frontiers in genetics · 2024Article
- Identification of TIMP1-induced dysregulation of epithelial-mesenchymal transition as a key pathway in inflammatory bowel disease and small intestinal neuroendocrine tumors shared pathogenesis.Frontiers in genetics · 2024Article
- Selected Cytokines and Metalloproteinases in Inflammatory Bowel Disease.International journal of molecular sciences · 2023Review
- An Analysis of the Content of Metalloproteinases in the Intestinal Wall of Patients with Crohn's Disease.Life (Basel, Switzerland) · 2023Article
- Small nucleolar RNAs and SNHGs in the intestinal mucosal barrier: Emerging insights and current roles.Journal of advanced research · 2023Review
- Article
- Inflammatory Bowel Disease-Associated Gut Commensals Degrade Components of the Extracellular Matrix.mBio · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Crohn's disease (CD) and ulcerative colitis (UC) belong to a group of inflammatory bowel diseases (IBD). The aim of our study was to evaluate the expression of MMP-2, MMP-7, MMP-9, TIMP-1, and TIMP-2 in ulcerative colitis and Crohn's disease. The study group comprised 34 patients with UC and 10 patients with CD. Evaluation of MMP-2, MMP-7, MMP-9, TIMP-1, and TIMP-2 expression in tissue samples was performed using immunohistochemistry. The overexpression of MMP-9 and TIMP-1 was dominant in both the glandular epithelium and inflammatory infiltration in UC patients. In contrast, in CD subjects the positive expression of MMP-2 and TIMP-1 was in glandular tubes while mainly MMP-7 and TIMP-2 expression was in inflammatory infiltration. Metalloproteinases' expression was associated with the presence of erosions, architectural tissue changes, and inflammatory infiltration in the lamina propria of UC patients. The expression of metalloproteinase inhibitors correlated with the presence of eosinophils and neutrophils in UC and granulomas in CD patients. Our studies indicate that the overexpression of metalloproteinases and weaker expression of their inhibitors may determine the development of IBD. It appears that MMP-2, MMP-7, and MMP-9 may be a potential therapeutic target and the use of their inhibitors may significantly reduce UC progression.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.